Effect of vitamin D3 on mild to moderate CTDs and TS children aged 6-13 years

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056482

Enrollment

Unknown

Registered

2022-02-06

Start date

2022-02-07

Completion date

Unknown

Last updated

2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tic disorder

Interventions

Low dose vitamin D3 treatment group:Supplement with low-dose vitamin D3

High dose vitamin D3 treatment group:Supplement with high-dose vitamin D3

Eligibility

Sex/Gender

All

Age

6 Years to 13 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of DSM-5 mild to moderate CTDs or TS; 2. Serum 25(OH)D < 30ng/ml; 3. Aged between 6 and 13; 4. The guardian agrees to participate in the study and signs the informed consent.

Exclusion criteria

Exclusion criteria: 1. Other neuropsychiatric disorders (such as autism spectrum disorder, mental disorders, tuberous sclerosis, epilepsy, attention deficit hyperactivity disorder and obsessive-compulsive disorder), rheumatic fever; 2. Receive any medications associated with tic disorders and comorbidities, especially antipsychotics, SSRIs, or psychostimulants; 3. Elevated blood calcium; 4. The patient or the patient's guardian refuses to evaluate or discontinue treatment.

Design outcomes

Primary

Measure	Time frame
Yale Global Tic Severity Scale;Evaluation of comorbidity;Clinical global impression, CGI;	—

Secondary

Measure	Time frame
25(OH)D;Blood calcium level;	—

Countries

China

Contacts

Public ContactJia Feiyong

First Hospital of Jilin University

erkekangfujia@163.com+86 13943003914

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026